EZH2 and breast carcinoma: In breast cancer, this K29- and K33-specific DUB binds, deubiquitinates, and stabilizes the enhancer of zeste homologue (EZH2) catalytic component of the gene silencing Polycomb repressive complex 2 (PRC2) to promote growth, resulting in poor prognosis [66].